Free Trial
NASDAQ:MGRX

Mangoceuticals Q2 2024 Earnings Report

Mangoceuticals logo
$0.34 -0.02 (-6.06%)
Closing price 06/9/2026 04:00 PM Eastern
Extended Trading
$0.34 0.00 (-0.29%)
As of 05:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mangoceuticals EPS Results

Actual EPS
-$20.25
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Mangoceuticals Revenue Results

Actual Revenue
$0.16 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mangoceuticals Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Thursday, August 15, 2024
Conference Call Time
7:00AM ET

Mangoceuticals Earnings Headlines

Mangoceuticals (NASDAQ:MGRX) Upgraded at Wall Street Zen
Mangoceuticals Inc
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before major runs - says the window to get in early is closing fast. Brown is showing investors how to claim a stake in Elon Musk's company before it hits the public markets. Once the IPO happens, this pre-public opportunity disappears.tc pixel
Mangoceuticals Inc.
See More Mangoceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mangoceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mangoceuticals and other key companies, straight to your email.

About Mangoceuticals

Mangoceuticals (NASDAQ:MGRX) develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

View Mangoceuticals Profile